Vonafexor
Sponsors
ENYO Pharma, Enyo Pharma
Conditions
Alport SyndromeImpaired renal function and suspected MASHNon-alcoholic Steatohepatitis
Phase 2
Safety, Tolerability, Pharmacokinetics and Efficacy of EYP001a in Patients With Nonalcoholic Steatohepatitis (NASH)
CompletedNCT03812029
Start: 2019-01-30End: 2021-07-06Updated: 2023-05-06
A study to Assess the Effect of Vonafexor on Kidney Function in Subjects With Impaired Renal Function and Suspected MASH
RecruitingCTIS2023-509192-16-00
Start: 2025-07-01Target: 50Updated: 2025-11-26
Vonafexor ALPort Syndrome Efficacy & Safety TRIAl-1 (ALPESTRIA-1)
CompletedNCT06425055
Start: 2024-08-01End: 2025-11-20Updated: 2026-02-09
Vonafexor fixed dose-escalation safety and proof-of-concept study in patients with at risk of progression Alport syndrome
CompletedCTIS2023-509638-20-00
Start: 2024-09-30End: 2025-09-30Target: 13Updated: 2025-10-03